Kidney Week

Abstract: TH-PO743

Benefits of Glucagon-Like Peptide 1 Receptor Agonists in Kidney Transplant Recipients

Session Information

• Transplantation: Clinical - 1
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

• 2102 Transplantation: Clinical

Authors

• Garcia Valencia, Oscar Alejandro, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Oscar Alejandro Garcia Valencia, MD

• Sahi, Sukhdeep Singh, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Sukhdeep Singh Sahi, MBBS

• Na_, Jie, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Jie Na_, MS

• Smith, Byron H., Mayo Clinic Minnesota, Rochester, Minnesota, United States

Byron H. Smith, MS, PhD

• Budhiraja, Pooja, Mayo Clinic Arizona, Scottsdale, Arizona, United States

Pooja Budhiraja, MD, FASN

• Diwan, Tayyab S., Mayo Clinic Minnesota, Rochester, Minnesota, United States

Tayyab S. Diwan, MD

• Issa, Naim S., Mayo Clinic Minnesota, Rochester, Minnesota, United States

Naim S. Issa, MD, FASN

• Denic, Aleksandar, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Aleksandar Denic, MD, PhD

• Abdelrheem, Ahmed, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Ahmed Abdelrheem, MD

• Wadei, Hani, Mayo Clinic in Florida, Jacksonville, Florida, United States

Hani Wadei, MD, FASN

• Kudva, Yogish C., Mayo Clinic Minnesota, Rochester, Minnesota, United States

Yogish C. Kudva, MD

• Kukla, Aleksandra, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Aleksandra Kukla, MD

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) showed improved outcomes in patients with type 2 diabetes (DM2), however limited studies exist in kidney transplant recipients (KTR).

Methods

We retrospectively studied patient and allograft outcomes in KTR treated with GLP-1 RA for at least 12 months vs a reference group (DM2 with not treated with GLP-1 RA).

Results

Demographics of both cohorts are presented in Table 1. The mean (SD) follow-up for GLP-1 RA and reference group was 6.9 (4.4) and 6.8 (4.2) years, respectively. The use of GLP-1 RA was associated with significantly better survival (p=0.03); Fig. 1, improved mean urine albumin/creatinine ratio (decreased by 31 mg/g/year vs increased by 20.47 mg/g/year; p <.001), eGFR (increased by 0.52 mL/min/BSA/y vs decreased by 1.56 mL/min/BSA/y, p= 0.044) and triglycerides (decreased by 2.17 mg/dl/y and decreased by 2.3 mg/dl/y; p=.04) in GLP1RA treated patients versus not, respectively.

Conclusion

GLP1RA may potentially improve survival and may positively impact kidney endpoints. Limitations include the retrospective study design and potential bias related to patient selection for GLP-1 RA therapy. Prospective studies with patient survival and renal endpoints are needed.